학술논문

Results of a randomized, double-blind, placebo controlled, phase 2 study investigating the safety and efficacy of anti-factor XIIa monoclonal antibody garadacimab (CSL312) for prophylaxis of HAE
Document Type
Journal
Source
ALLERGY AND ASTHMA PROCEEDINGS; NOV 1 2022, 43 6, p562-p562, 1p.
Subject
Language
English
ISSN
15396304